Catalysts
ABUS Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
ABUSArbutus Biopharma Corp
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum51
- Value92
- Quality82
- Risk resilience62
- Sentiment—
Stock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 51/100 and sentiment — before the next covered event.
Updated Nov 15, 2026 · Sentiment 50.00%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | — | -$0.02 | $0.30 | +1393.1% | $1M | $299K |
| Aug 12, 2026 | — | -$0.02 | -$0.03 | -50.0% | $700K | $1.01M |
| May 13, 2026 | — | -$0.03 | $0.87 | +3000.0% | $750K | $179.13M |
| Mar 23, 2026 | — | -$0.04 | -$0.01 | +71.5% | $614.5K | $1.05M |
| Nov 13, 2025 | — | -$0.06 | -$0.04 | +28.6% | $841K | $529K |
| Aug 6, 2025 | — | -$0.02 | $0.01 | +150.0% | $1.59M | $10.74M |
| May 14, 2025 | — | -$0.09 | -$0.13 | -44.4% | $2.24M | $1.76M |
| Mar 27, 2025 | — | -$0.08 | -$0.07 | +12.5% | $2.26M | $1.57M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Arbutus Biopharma Stock Rises 11% On Launch Of $230 Mln Share Buyback
Shares of Arbutus Biopharma Corporation (ABUS) are gaining about 11 percent on Friday morning after the company announced its plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent settlement with Moderna to shareholders.
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified "Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ('Arbutus” or the 'Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified 'Dutch Auction” tender offer (the 'Offer”) to repurchase up to US$230 million of its common shares at a purchase price of not less than US$5.00 per share and not more than US$5.75 per share, in cash, less any applicable withholding taxes and without interest. The Offer is expected to commence on or about August 24, 2026 and, unless extended or terminated by the Company, expire on or about September 29, 2026. The Offer is expected to be funded through the Company’s cash on hand.
Related Links
ABUS Catalysts FAQ
What are the next catalysts for ABUS stock?
ABUS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move ABUS stock?
Upcoming events that could move ABUS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could ABUS's next earnings report affect the stock?
ABUS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive ABUS stock higher?
ABUS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt ABUS stock?
ABUS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.